Publications by authors named "James F List"

Claim this Profile
T
The authors reply.
Donald E Kohan, Paola Fioretto, Weihua Tang, James F List

Kidney Int· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.
Agata Ptaszynska, Kristina M Johnsson, Shamik J Parikh, Tjerk W A de Bruin, Anne Marie Apanovitch, James F List

Drug Saf· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.
Kristina M Johnsson, Agata Ptaszynska, Bridget Schmitz, Jennifer Sugg, Shamik J Parikh, James F List

J Diabetes Complications· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urinary tract infections in patients with diabetes treated with dapagliflozin.
Kristina M Johnsson, Agata Ptaszynska, Bridget Schmitz, Jennifer Sugg, Shamik J Parikh, James F List

J Diabetes Complications· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.
Donald E Kohan, Paola Fioretto, Weihua Tang, James F List

Kidney Int· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Linong Ji, Jianhua Ma, Hongmei Li, Traci A Mansfield, Caroline L T'joen, James F List

Clin Ther· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
Clifford J Bailey, Jorge L Gross, Delphine Hennicken, Nayyar Iqbal, Traci A Mansfield, James F List

BMC Med· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.
Jean M Whaley, Mark Tirmenstein, Timothy P Reilly, Simon M Poucher, Joanne Saye, James F List

Diabetes Metab Syndr Obes· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.
Julio Rosenstock, Marisa Vico, Li Wei, Afshin Salsali, James F List

Diabetes Care· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
Serge A Jabbour, Jean M Whaley, Mark Tirmenstein, Simon M Poucher, Timothy P Reilly, James F List

Postgrad Med· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.
James F List, Jean M Whaley

Kidney Int Suppl· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.
Ele Ferrannini, Silvia Jimenez Ramos, Afshin Salsali, Weihua Tang, James F List

Diabetes Care· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergy between scientific advancement and technological innovation, illustrated by a mechanism-based model characterizing sodium-glucose cotransporter-2 inhibition.
Liping Zhang, Chee M Ng, James F List, Marc Pfister

J Clin Pharmacol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
Clifford J Bailey, Jorge L Gross, Anne Pieters, Arnaud Bastien, James F List

Lancet· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.
John P H Wilding, Paul Norwood, Caroline T'joen, Arnaud Bastien, James F List

Diabetes Care· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
James F List, Vincent Woo, Enrique Morales, Weihua Tang, Fred T Fiedorek

Diabetes Care· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin.
James F List, Huile He, Joel F Habener

Regul Pept· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4.
Norihiko Ogawa, James F List, Joel F Habener, Takashi Maki

Diabetes· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells.
James F List, Joel F Habener

Am J Physiol Endocrinol Metab· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defective melanocortin 4 receptors in hyperphagia and morbid obesity.
James F List, Joel F Habener

N Engl J Med· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis